US$ 21.08
glp-1 receptor agonists cardiovascular benefits and drawbacks of agonist use. Abbreviations: GLP-1 Receptor Agonists in the
Description
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action

Several candidates are advancing through clinical development, including orforglipron, currently in Phase III trials for obesity and type 2 diabetes

Reddys Laboratories (DRL) and OneSource Specialty Pharma Ltd (OSSPL) from selling semaglutide domestically in a patent infringement suit filed by Novo Nordisk, a Danish drug manufacturer (pdf)
doi: 10.1007/s00125-016-3874-y, 37 FeinglosM

Smits, M
